Pharma Clinical Trial Services: World Market 2013-2023
NEW YORK, March 4, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Report DetailsDiscover new trends, opportunities and prospects for contract clinical trials
What's the outlook for clinical research providers? Visiongain's updated report gives you forecasted revenues to 2023. It explains trends, opportunities and commercial prospects.Our study lets you assess sales data at overall world market, submarket and national level. There you find the most promising and lucrative areas in clinical trial outsourcing, helping your research and analyses. Forecasts and other analyses to help you stay ahead in knowledge In our work you find revenue forecasting to 2023, historical data, growth rates and market shares. Also, you see qualitative analysis (SWOT and STEP), business news, outlooks and developmental trends (R&D). You receive 74 tables, 61 charts and two survey interviews. There's rising demand for that pharma research. The outsourced clinical trials market will increase its revenues from 2013 to 2023, achieving strong growth. Clinical research organisations (CROs) and their clients will benefit. The following sections show what you find in our new report. Discover prospects for the world market and submarkets Along with revenue prediction for the overall world market, you see forecasts to 2023 for eight submarkets:• Early phase clinical trial services• Late phase services. We also show forecasts for contract services by therapeutic area: • Cancers • Central nervous system (CNS) diseases • Cardiovascular diseases • Infections • Metabolic disorders • Other therapy areas (grouped prediction). You gain advantages by understanding trends, opportunities and challenges. Our investigation shows what will stimulate and restrain business for CROs. Our work also breaks the main world forecast into geographical markets.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts